ClinicalTrials.gg
RecruitingNCT07287397ALSUpdated Nov 13, 2026

Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

A Phase 1/2 interventional study of VTx-002 and Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone in Amyotrophic Lateral Sclerosis, sponsored by Vector Y Therapeutics. Recruiting at 9 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Vector Y Therapeutics · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 6, 2026Enrollment updated1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Planned enrollment
149th of 307
36 · median 33
Started
2025
with 26 others
Phase 1/2
32 of 440
9 open now
Primary completion
2027-10
later than 66 of 128 live
Registered
408th of 440
by date

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 149th largest by planned enrollment of the 307 interventional ones that give a count, is one of 27 that started in 2025, is one of 32 in phase 1/2, reaches primary completion later than 66 of the 128 other live ones, and was the 408th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

PIONEER-ALS is a Phase 1/2, multicenter, open-label, ascending dose, uncontrolled, first-in-human study that will evaluate the safety, tolerability and effects on clinical and biomarker endpoints of intracisternal administration of Vtx-002 in participants with Amyotrophic Lateral Sclerosis (ALS).

Two escalating dose (low dose and high dose) cohorts are planned. The duration of the study will be a maximum of 5 years and 5 weeks (265 weeks) for each participant. The screening period may last up to 5 weeks to complete screening procedures.

Read the detailed description

All participants will receive a single injection of the study drug. During the first year of the study there will be 12 visits to the study center, including an overnight stay after dosing of at least 1 night. There will be a further 4 remote visits (telephone or video call).

From Year 2-5 there will be 8 further visits. These will be every 6 months and will be either in-person at the study site or remote (telephone or video call) if needed or preferred.

Throughout the 5-year observation period, there will be up to 20 study visits to complete follow-up tests and assessments and monitor the ongoing effects of the study drug.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • ALS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Capable of, and willing to, provide written and comply with study procedures, including visits to the study site and visit requirements
  2. Male or female ≥ 18 years of age
  3. Has a diagnosis of ALS according to the El Escorial criteria (Brooks, et al., 2000) (probable, laboratory results supported; clinically probable, clinically definite)
  4. Confirmed absence of ALS caused by FUS and SOD1 gene mutations confirmed by laboratory tests.
  5. A maximum of 18 months since first appearance of weakness (e.g., limb weakness, dysarthria, dysphagia, shortness of breath)
  6. Erect (seated) SVC % predicted ≥ 80% at Screening
  7. Treatment Research Initiative to Cure ALS (TRICALS) risk score between -2 and -6 at Screening
  8. Has a reliable caregiver/partner/legal representative willing and able to support the participant in participation in the study and to give informed consent on behalf of the participant in the case that disease progression prevents the participant of giving consent (local legal rules will apply).
  9. Treatment with riluzole and/or edaravone is allowed if treatment was started and has remained at a stable dose for at least 2 weeks (riluzole) or one treatment cycle (edaravone) before the Screening visit
  10. Women of (WOCBP) and male participants with female partners who are WOCBP must agree to use highly effective during and after the study. WOCBP cannot be pregnant or breastfeeding
  11. Women of nonchildbearing potential must be or surgically sterile (e.g. hysterectomy, bilateral tubal ligation, ovaries removed)

Key Exclusion Criteria:

  1. Diagnosis of a significant CNS or peripheral nervous system disease other than ALS that may be a cause for the participant's ALS symptoms or may confound study objectives
  2. Spinal, cervical, or brain MRI/MRA indicating abnormality
  3. Presence of tracheostomy and feeding tube at Screening
  4. to use (e.g. due to osteoporosis, uncontrolled blood pressure, diabetes or cholesterol).

5. Significant concomitant disease or condition within 6 months of Screening that could pose an unacceptable safety risk to the participant or interfere with the participant's ability to comply with study procedures, e.g. heart disease, uncontrolled diabetes, liver disease, diseases needing strong immune-suppressing drugs, cancer, etc or a current psychiatric diagnosis.

6. Clinically significant abnormalities in laboratory test results at Screening for example poor liver or kidney function, abnormal clotting or infections such as Hepatitis or

7. Use of blood thinners (e.g., warfarin, heparin, and novel oral anticoagulants) and being unable to safely stop them before certain study procedures.

8. Contraindications to imaging methods MRI, MRA, CT due to claustrophobia and/or intolerance to contrast agents.

9. Contraindications to general anaesthesia (GA) or deep sedation

10 Positive test for illegal drugs (except prescribed medications or permitted medicinal/recreational marijuana if used responsibly)

11. Generally frail or if the Investigator deems participation in the study would not be in the best interest of the participant or is likely to prohibit further participation during the study

Other protocol-defined inclusion/exclusion criteria may apply

-

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Gene Therapy Group 1: Dose 1 (Low Dose)

    Gene Therapy: VTx-002 18 participants will receive dose 1 administered intra cisterna magna. Dosing of the first 3 participants will be staggered at specific timepoints apart and with a safety monitoring committee review of health-related information in between each participant being dosed. VTx-002 is a single dose therapy Drug: Preventative (Prophylactic) Medication: Methylprednisolone

    Genetic: VTx-002 · Drug: Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone

  • Experimental
    Gene Therapy Group 2: Dose 2 (High Dose)

    Gene Therapy: VTx-002 18 participants will receive dose 2 administered intra cisterna magna. The participant dosing in group 2 will be staggered as it was in group 1. VTx-002 is a single dose therapy. Drug: Preventative (Prophylactic) Medication - Methylprednisolone

    Genetic: VTx-002 · Drug: Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone

Interventions

  • GeneticVTx-002

    An investigational gene therapy targeting a specific protein.

  • DrugPreventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone

    To reduce the risk of reactions caused by the study treatment, steroid medicines will be given in advance.

    Also known as: Prednisone, Prednisolone

06

What researchers measure

Primary outcomes

  1. The number of participants with treatment related adverse events (AEs) and Serious Adverse Events (SAEs)

    Assessed by reviewing the nature, incidence, severity, relatedness, seriousness and outcome of treatment emergent adverse events.

    Time frame: Over 5 years

  2. The number of participants with treatment related adverse events (AEs) and Serious Adverse Events (SAEs)

    Assessed by reviewing laboratory values

    Time frame: Over 5 years

  3. The number of participants with treatment related adverse events (AEs) and Serious Adverse Events (SAEs)

    Assessed by reviewing Magnetic Resonance Imaging (MRI) findings.

    Time frame: Over 5 years

  4. The number of participants with treatment related adverse events (AEs) and Serious Adverse Events (SAEs)

    Assessed by review of Treatment Induced Peripheral Neuropathy Assessment Scale (TNAS) \*TNAS a brief participant-reported questionnaire used to measure the severity and progression of peripheral neuropathy. Each item is rated on a scale of 0 to 10, where 0 means no symptom and 10 means the symptom is as bad as it can possibly be.

    Time frame: over 5 years

  5. The number of participants with treatment related adverse events (AEs) and Serious Adverse Events (SAEs)

    Assessed by reviewing cellular responses by analyzing blood samples.

    Time frame: Over 5 years

  6. The number of participants with treatment related adverse events (AEs) and Serious Adverse Events (SAEs)

    Assessed by reviewing scores of the Columbia Suicide Severity Rating Scale (C-SSRS) \*C-SSRS is a widely used, evidence-based suicide risk assessment tool that helps identify whether someone is at risk for suicide and gauge the level of support needed. A low score is associated with a lower risk level in this brief questionnaire.

    Time frame: Over 5 years

  7. The number of participants with treatment related adverse events (AEs) and Serious Adverse Events (SAEs)

    Assessed by performing 4 formal interim analyses 1. 6 months after Gene Therapy Group 1 receive the single dose treatment 2. 6 months after Gene Therapy Group 2 receive the single dose treatment 3. 12 months after Gene Therapy Group 1 receive the single dose treatment 4. 12 months after Gene Therapy Group 2 receive the single dose treatment

    Time frame: At month 6 and month 12

Secondary outcomes

  1. To assess whether VTx-002 works to prevent the progression of ALS and what dose can be used for future clinical studies.

    Changes certain blood values

    Time frame: At month 6 and month 12

  2. To assess whether VTx-002 works to prevent the progression of ALS and what dose can be used for future clinical studies.

    Time to assisted permanent ventilation or death

    Time frame: over 12 months

  3. To assess whether VTx-002 works to prevent the progression of ALS and what dose can be used for future clinical studies.

    Immune responses assessed by analyzing blood samples

    Time frame: Over 5 years

  4. To assess whether VTx-002 works to prevent the progression of ALS and what dose can be used for future clinical studies.

    Change in Slow Vital Capacity

    Time frame: At month 6 and month 12

  5. To assess whether VTx-002 works to prevent the progression of ALS and what dose can be used for future clinical studies.

    Changes in CSF values

    Time frame: At month 6 and month 12

  6. To assess whether VTx-002 works to prevent the progression of ALS and what dose can be used for future clinical studies.

    Change in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)

    Time frame: At month 6 and month 12 *ALSFRS-R is a scale used to monitor disease progression. The 12 questions. Questions are scored from 0 to 4, with a maximum score of 48 indicating full function and a minimum score of 0 indicating significant impairment.

Other outcomes

  1. To assess changes in biomarkers

    Analysis of blood samples to assess viral shedding

    Time frame: Over 5 years

  2. To assess changes in muscle strength assessments from baseline.

    Change in muscle strength measured by Hand-held Dynamometry

    Time frame: Measured at month 6 and month 12

  3. To assess disease severity and improvement

    Disease severity and improvement measured using the Clinical Global Impression (CGI) scales for Severity (CGI-S) and Improvement (CGI-I). The CGI scales each use a seven-point scale where 1 indicates less severe (CGI-S) or most improved (CGI-I) and 7 indicates more severe illness (CGI-S) or worsening of condition (CGI-I)

    Time frame: over 12 months

  4. To assess immunogenicity of VTx002

    Assessed by the review of the immunogenicity to the capsid and transgene by analyzing blood samples.

    Time frame: Over 5 years

  5. To assess changes Health Related Quality of Life

    Change in Health Related Quality of Life measured using the EQ5D-L questionnaire. \*The EQ5D-L is a self-completed questionnaire assessing five core dimensions (Mobility, Self-care, Usual Activities, Pain/Discomfort, Anxiety/Depression). It is scored by combining patient responses across the five dimensions and then converting to a single utility score whereby 1.0 indicates perfect health and 0 indicates death

    Time frame: Measured at month 6 and month 12

  6. To assess changes Health Related Quality of Life

    Change in Health Related Quality of Life measured using the ALSAQ-5 questionnaire. \*The ALSAQ-5 is a brief, 5-item questionnaire used to measure the impact of Amyotrophic Lateral Sclerosis on a patient's quality of life. Five key areas are rated for difficulties and converted to a total score from 0 (worst) to 100 (best)

    Time frame: Measured at month 6 and month 12

07

Study locations

7 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Oct 2027, 21 months after the start.

Of 36 phase 1/2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 57. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Dec 17, 2025
StartActual
Dec 19, 2025
Primary completionEst.
Oct 15, 2027
CompletionEst.
Oct 15, 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 3 sites removed
Show site
  • The Eleanor & Lou Gehrig ALS Center · New York, United States
Show 3 removed
  • University of Miami School of Science · Miami, United States
  • Herbert Irving Comprehensive Cancer Center · New York, United States
  • Kings College Hospital · London, United Kingdom
Nov 6, 2026
Enrollment
12→36
Oct 16, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • The Eleanor & Lou Gehrig ALS Center · New York, United StatesContact person changed (no phone or email listed)
Nov 13, 2026
Show all 4 updates
  1. Nov 13, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • The Eleanor & Lou Gehrig ALS Center · New York, United StatesContact person changed (no phone or email listed)
  2. Nov 6, 2026
    1 site added, 3 sites removed
    Show site
    • The Eleanor & Lou Gehrig ALS Center · New York, United States
    Show 3 removed
    • University of Miami School of Science · Miami, United States
    • Herbert Irving Comprehensive Cancer Center · New York, United States
    • Kings College Hospital · London, United Kingdom
  3. Oct 30, 2026
    Minor edits only
    + 1 other change: arm descriptions
  4. Oct 16, 2026
    Enrollment 12→36
    + 1 other change: design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07287397
Lead sponsor
Vector Y Therapeutics
Responsible party
Sponsor
First posted
Dec 17, 2025
Start date
Dec 19, 2025
Primary completion
Oct 15, 2027 (estimated)
Completion
Oct 15, 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Dr Olga Uspenskaya Chief medical Officer, VectorY Therapeutics, M.D; PhD
Contact
patients@vectorytx.com
patients@vectorytx.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion